← Eichor
Condition: Recurrent Multiple Myeloma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Phase N/A · 4 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06767254Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05363111A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4 · 1 location(s) · University Health Network, Toronto · NCT06251076Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Zhejiang ACEA Pharmaceutical Co. Ltd. · NCT05565807A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07609030CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · 266 location(s) · Celgene · NCT05519085Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT06465316A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
Phase N/A · 1 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06874530Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Phase N/A · 1 location(s) · Sung-Soo Park · NCT07051850A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Pre
Phase 3 · 62 location(s) · Grifols Therapeutics LLC · NCT05645107Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 · 1 location(s) · O&D BioTech Group CO., Limited · NCT07369895Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple
NA · 1 location(s) · Roswell Park Cancer Institute · NCT05312255Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT05922501A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Partic
Phase 1 · 14 location(s) · Genentech, Inc. · NCT05927571Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06581640A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Phase 1 · 1 location(s) · He Huang · NCT06084962Selinexor and Backbone Treatments of Multiple Myeloma Patients
Phase 1/Phase 2 · 25 location(s) · Karyopharm Therapeutics Inc · NCT02343042Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed
Phase 2 · 52 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT062972263'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.